Integrated multidisciplinary approach/Agrica MSA IFR Public Health 99

https://www.neurodegenerationresearch.eu/survey/integrated-multidisciplinary-approachagrica-msa-ifr-public-health-99/

Title of cohort

Integrated multidisciplinary approach/Agrica MSA IFR Public Health 99

Acronym for cohort

AMI

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Jean-François

Name of Principal Investigator - Last name

DARTIGUES

Address of institution -Institution

ISPED / INSERM U1219 / Université de Bordeaux

Address of institution - Street address

146 rue Léo Saignat

Address of institution - City

Bordeaux

Address of institution - Postcode

33076

Country

France

Website

Contact email

Funding source

MSA (Gironde et caisse centrale), AGRICA

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

Study of the disease, especially in association with age. Study health care use and social measures for Alzheimers disease and similar syndromes. Compare with the urban areas (3C and PAQUID)

Q2b. What distinguishes this cohort from other population cohorts?

Population-based cohort. Rural population retired from agriculture

Q3a. i) Number of publications that involve use of your cohort to date

4

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

http://www.ncbi.nlm.nih.gov/pubmed/?term=AMI+AND+Dartigues[Author]

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

65

Q4a. Study criteria: what is the age range of participants at recruitment? To:

until death

Q4b. Study criteria: what are the inclusion criteria?

65 or more years old subjects. Retired from an agricultural activity. Resident in one of the

selected towns of the countryside of Gironde. Affiliated to MSA and having, for the employees, the AGRICA complementary (70% of the sample). General practitioner in Gironde

Q4c. Study criteria: what are the exclusion criteria?

Not being affiliated to MSA

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

1,000-5,000 participants

Q6a. Please describe what measures are used to characterise participants

Sociodemographic characteristics, lifestyle, medical antecedents, medications, depressive symptomatology and activity limitations were assessed at baseline and each follow-up time. A complete cognitive evaluation with systematic screening for dementia was performed at baseline and each follow-up time. Fasting blood samples were collected at baseline. Brain MRI were performed at baseline and follow-up on a subsample.

Q6b. Are there additional measures for participants with a clinical disorder?

Examination by a neurologist or a geriatrician

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

Yes

If yes please specify

Primary endpoint: dementia; secondary endpoints: several co-morbidities, among them Parkinson, cancer, diabetes

Q7. What is the study design (select all that apply)?

Longitudinal| Prospective cohort

Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?

Yes

Q9b. If your study includes a specialised subset of control participants please describe

Participants free of the disease can be used as controls

Q10a. i) Please enter the data collection start date

01/09/2007

Q10a. ii) Please enter the data collection end date

Last follow-up: 2016; however a next follow-up is planned

Q10a. iii) Is data collection for this study

Data collection ongoing| Data analysis ongoing| Closed to new patients

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Is data collected

Only through the study

Other please specify here

Mainly through the study + health insurance data + cancer registry

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

% available

100

Q13a. Please give information on the format and availability of data stored in a database (2)

No

% available
Q13a. Please give information on the format and availability of data stored in a database (3)

No

% available
Q13a. Please give information on the format and availability of data stored in a database (4)

No

% available

Other (please specify)
% available
Q13b. Please give information on the format and availability of data held as individual records (1)

Data is held as individual records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (2)

No

% available
Q13b. Please give information on the format and availability of data held as individual records (3)

Data held on computer based records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (4)

No

% available
Please specify language used

French

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| Access committee mechanism

Q15. What data sharing policy is specified as a condition of use?

No policy exists

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Living donors: blood| Living donors: blood derivatives| Living donors: DNA

Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

No

Number of Patients
% of total cohort

Types:
Population Cohorts

Member States:
France

Diseases:
Neurodegenerative disease in general

Years:
2016

Database Categories:
N/A

Database Tags:
N/A